Jean Joel Bigna1, Aude Laetitia Ndoadoumgue2, Jobert Richie Nansseu3,4, Joel Noutakdie Tochie5, Ulrich Flore Nyaga6, Jan René Nkeck6, Audrey Joyce Foka6,7, Arnaud D Kaze8, Jean Jacques Noubiap9. 1. Department of Epidemiology and Public Health, Centre Pasteur of Cameroon, Yaoundé, Cameroon. 2. School of Health and Related Research, The University of Sheffield, Sheffield, UK. 3. Department of Public Health, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé. 4. Department of Disease, Epidemics and Pandemics Control, Ministry of Public Health, Yaoundé. 5. Department of Anesthesiology and Critical Care Medicine, Faculty of Medicine. 6. Department of Internal Medicine and Specialties, Faculty of Medicine and Biomedical Sciences, University of Yaoundé I, Yaoundé, Cameroon. 7. School of Public Health, Faculty of Medicine, University of Paris-Sud XI, Le Kremlin-Bicêtre, France. 8. Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA. 9. Centre for Heart Rhythm Disorders, University of Adelaide and Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Abstract
BACKGROUND: Although HIV infection and antiretroviral therapy (ART) increase the risk for hypertension in people living with HIV (PLHIV), the global and regional burden of hypertension in PLHIV is not well characterized. METHODS: In this systematic review and meta-analysis, we searched multiple databases for studies reporting on hypertension in PLHIV and conducted between 2007 and 2018. Meta-analysis through random-effect models served to obtain the pooled prevalence estimates. Heterogeneity was assessed via the χ test on Cochran's Q statistic. RESULTS: We included 194 studies (396 776 PLHIV from 61 countries). The global prevalence of hypertension was 23.6% [95% confidence interval (95% CI: 21.6-25.5)] with substantial heterogeneity. The regional distribution was Western and Central Europe and North America [28.1% (95% CI: 24.5-31.9)], West and Central Africa [23.5% (16.6-31.0)], Latin America and the Caribbean [22.0% (17.8-26.5)], Eastern and Southern Africa [19.9% (17.2-22.8)], and Asia and Pacific [16.5% (12.5-21.0)]; P = 0.0007. No study originated from the Middle East and North Africa, and Eastern Europe and Central Asia regions. The prevalence was higher in high-income countries than others (P = 0.0003) and higher in PLHIV taking ART than those ART-naive (P = 0.0003). The prevalence increased over time (mainly driven by Eastern and Southern Africa) and with age. There was no difference between men and women. We estimated that in 2018, there were 8.9 (95% CI: 8.3-9.6) million cases of hypertension in PLHIV globally, among whom 59.2% were living in Sub-Saharan Africa. CONCLUSION: Cost-effective strategies to curb the dreadful burden of hypertension among PLHIV are needed.
BACKGROUND: Although HIV infection and antiretroviral therapy (ART) increase the risk for hypertension in people living with HIV (PLHIV), the global and regional burden of hypertension in PLHIV is not well characterized. METHODS: In this systematic review and meta-analysis, we searched multiple databases for studies reporting on hypertension in PLHIV and conducted between 2007 and 2018. Meta-analysis through random-effect models served to obtain the pooled prevalence estimates. Heterogeneity was assessed via the χ test on Cochran's Q statistic. RESULTS: We included 194 studies (396 776 PLHIV from 61 countries). The global prevalence of hypertension was 23.6% [95% confidence interval (95% CI: 21.6-25.5)] with substantial heterogeneity. The regional distribution was Western and Central Europe and North America [28.1% (95% CI: 24.5-31.9)], West and Central Africa [23.5% (16.6-31.0)], Latin America and the Caribbean [22.0% (17.8-26.5)], Eastern and Southern Africa [19.9% (17.2-22.8)], and Asia and Pacific [16.5% (12.5-21.0)]; P = 0.0007. No study originated from the Middle East and North Africa, and Eastern Europe and Central Asia regions. The prevalence was higher in high-income countries than others (P = 0.0003) and higher in PLHIV taking ART than those ART-naive (P = 0.0003). The prevalence increased over time (mainly driven by Eastern and Southern Africa) and with age. There was no difference between men and women. We estimated that in 2018, there were 8.9 (95% CI: 8.3-9.6) million cases of hypertension in PLHIV globally, among whom 59.2% were living in Sub-Saharan Africa. CONCLUSION: Cost-effective strategies to curb the dreadful burden of hypertension among PLHIV are needed.
Authors: Julian T Hertz; Sainikitha Prattipati; Godfrey L Kweka; Jerome J Mlangi; Tumsifu G Tarimo; Blandina T Mmbaga; Nathan M Thielman; Francis M Sakita; Matthew P Rubach; Gerald S Bloomfield; Preeti Manavalan Journal: Glob Public Health Date: 2022-03-13
Authors: Katherine Davis; Pablo Perez-Guzman; Annika Hoyer; Ralph Brinks; Edward Gregg; Keri N Althoff; Amy C Justice; Peter Reiss; Simon Gregson; Mikaela Smit Journal: BMC Med Date: 2021-05-13 Impact factor: 8.775
Authors: Ayukafangha Etando; Adefolarin A Amu; Mainul Haque; Natalie Schellack; Amanj Kurdi; Alian A Alrasheedy; Angela Timoney; Julius C Mwita; Godfrey Mutashambara Rwegerera; Okwen Patrick; Loveline Lum Niba; Baffour Boaten Boahen-Boaten; Felicity Besong Tabi; Olufunke Y Amu; Joseph Acolatse; Robert Incoom; Israel Abebrese Sefah; Anastasia Nkatha Guantai; Sylvia Opanga; Ibrahim Chikowe; Felix Khuluza; Dan Kibuule; Francis Kalemeera; Ester Hango; Jennie Lates; Joseph Fadare; Olayinka O Ogunleye; Zikria Saleem; Frasia Oosthuizen; Werner Cordier; Moliehi Matlala; Johanna C Meyer; Gustav Schellack; Amos Massele; Oliver Ombeva Malande; Aubrey Chichonyi Kalungia; James Sichone; Sekelani S Banda; Trust Zaranyika; Stephen Campbell; Brian Godman Journal: Healthcare (Basel) Date: 2021-12-13